Top

Published in:

01-07-2010 | Original Article

Optimized combination therapy using bortezomib, TRAIL and TLR agonists in established breast tumors

Authors: Sujin Lee, Hideo Yagita, Thomas J. Sayers, Esteban Celis

Published in: Cancer Immunology, Immunotherapy | Issue 7/2010

Abstract

TNF-related apoptosis-inducing ligand (TRAIL) is a member of the TNF family of cytokines, which can induce apoptosis in various tumor cells by engaging the receptors, DR4 and DR5. Bortezomib (Velcade) is a proteasome inhibitor that has been approved for patients with multiple myeloma. There is some experimental evidence in preclinical models that bortezomib can enhance the susceptibility of tumors to TRAIL-induced apoptosis. In this study, we investigated the effects of TRAIL-induced death using an agonistic antibody to the TRAIL receptor DR5 (α-DR5) in combination with bortezomib administered to mice previously injected with breast cancer cells (TUBO). This combination had some beneficial therapeutic effect, which was significantly enhanced by the co-administration of a Toll-like receptor 9 agonist (CpG). In contrast, single agent treatments had little effect on tumor growth. In addition, we evaluated the effect of combination with α-DR5, bortezomib, and CpG in the prevention/treatment of spontaneous mammary tumors in Balb-neuT mice. In this model, which is more difficult to treat, we observed dramatic antitumor effects of α-DR5, bortezomib and CpG combination therapy. Since such a mouse model more accurately reflects the immunological tolerance that exists in human cancer, our results strongly suggest that these combination strategies could be directly applied to the therapy for cancer patients.

Available only for authorised users

Assudani D, Cho HI, DeVito N, Bradley N, Celis E (2008) In vivo expansion, persistence, and function of peptide vaccine-induced CD8 T cells occur independently of CD4 T cells. Cancer Res 68:9892–9899CrossRefPubMed

Blade J, Cibeira MT, Rosinol L (2005) Bortezomib: a valuable new antineoplastic strategy in multiple myeloma. Acta Oncol 44:440–448CrossRefPubMed

Brooks AD, Ramirez T, Toh U, Onksen J, Elliott PJ, Murphy WJ, Sayers TJ (2005) The proteasome inhibitor bortezomib (Velcade) sensitizes some human tumor cells to Apo2L/TRAIL-mediated apoptosis. Ann N Y Acad Sci 1059:160–167CrossRefPubMed

Carpentier AF, Auf G, Delattre JY (2003) CpG-oligonucleotides for cancer immunotherapy: review of the literature and potential applications in malignant glioma. Front Biosci 8:e115–e127CrossRefPubMed

Cho HI, Niu G, Bradley N, Celis E (2008) Optimized DNA vaccines to specifically induce therapeutic CD8 T cell responses against autochthonous breast tumors. Cancer Immunol Immunother 57:1695–1703CrossRefPubMed

Corazza N, Kassahn D, Jakob S, Badmann A, Brunner T (2009) TRAIL-induced apoptosis: between tumor therapy and immunopathology. Ann N Y Acad Sci 1171:50–58CrossRefPubMed

Cotter TG (2009) Apoptosis and cancer: the genesis of a research field. Nat Rev Cancer 9:501–507CrossRefPubMed

Cotter TG, Lennon SV, Glynn JG, Martin SJ (1990) Cell death via apoptosis and its relationship to growth, development and differentiation of both tumour and normal cells. Anticancer Res 10:1153–1159PubMed

Cretney E, Takeda K, Smyth MJ (2007) Cancer: novel therapeutic strategies that exploit the TNF-related apoptosis-inducing ligand (TRAIL)/TRAIL receptor pathway. Int J Biochem Cell Biol 39:280–286CrossRefPubMed

10.

Dicato M, Boccadoro M, Cavenagh J, Harousseau JL, Ludwig H, San Miguel J, Sonneveld P (2006) Management of multiple myeloma with bortezomib: experts review the data and debate the issues. Oncology 70:474–482CrossRefPubMed

11.

Green DR, Bissonnette RP, Cotter TG (1994) Apoptosis and cancer. In: DeVita VT, Hellman S, Rosenberg SA (eds) Important advances in oncology. Lippincott, Philadelphia, pp 37–52

12.

Hallett WH, Ames E, Motarjemi M, Barao I, Shanker A, Tamang DL, Sayers TJ, Hudig D, Murphy WJ (2008) Sensitization of tumor cells to NK cell-mediated killing by proteasome inhibition. J Immunol 180:163–170PubMed

13.

Hao C, Song JH, Hsi B, Lewis J, Song DK, Petruk KC, Tyrrell DL, Kneteman NM (2004) TRAIL inhibits tumor growth but is nontoxic to human hepatocytes in chimeric mice. Cancer Res 64:8502–8506CrossRefPubMed

14.

Jung L, Holle L, Dalton WS (2004) Discovery, development, and clinical applications of bortezomib. Oncology (Williston Park) 18:4–13

15.

Kim JH, Majumder N, Lin H, Chen J, Falo LD Jr, You Z (2005) Enhanced immunity by NeuEDhsp70 DNA vaccine is needed to combat an aggressive spontaneous metastatic breast cancer. Mol Ther 11:941–949CrossRefPubMed

16.

Krieg AM (2002) CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol 20:709–760CrossRefPubMed

17.

McKenna SL, Cotter TG (1997) Functional aspects of apoptosis in hematopoiesis and consequences of failure. Adv Cancer Res 71:121–164CrossRefPubMed

18.

Meng Y, Carpentier AF, Chen L, Boisserie G, Simon JM, Mazeron JJ, Delattre JY (2005) Successful combination of local CpG-ODN and radiotherapy in malignant glioma. Int J Cancer 116:992–997CrossRefPubMed

19.

Monneret C, Buisson JP, Magdelenat H (2005) A new therapy with bortezomib, an oncologic medicinal product of the year 2004. Ann Pharm Fr 63:343–349PubMed

20.

Nava-Parada P, Forni G, Knutson KL, Pease LR, Celis E (2007) Peptide vaccine given with a Toll-like receptor agonist is effective for the treatment and prevention of spontaneous breast tumors. Cancer Res 67:1326–1334CrossRefPubMed

21.

Nencioni A, Wille L, Dal Bello G, Boy D, Cirmena G, Wesselborg S, Belka C, Brossart P, Patrone F, Ballestrero A (2005) Cooperative cytotoxicity of proteasome inhibitors and tumor necrosis factor-related apoptosis-inducing ligand in chemoresistant Bcl-2-overexpressing cells. Clin Cancer Res 11:4259–4265CrossRefPubMed

22.

Newsom-Davis T, Prieske S, Walczak H (2009) Is TRAIL the holy grail of cancer therapy? Apoptosis 14:607–623CrossRefPubMed

23.

Richardson PG (2004) A review of the proteasome inhibitor bortezomib in multiple myeloma. Expert Opin Pharmacother 5:1321–1331CrossRefPubMed

24.

Shanker A, Brooks AD, Tristan CA, Wine JW, Elliott PJ, Yagita H, Takeda K, Smyth MJ, Murphy WJ, Sayers TJ (2008) Treating metastatic solid tumors with bortezomib and a tumor necrosis factor-related apoptosis-inducing ligand receptor agonist antibody. J Natl Cancer Inst 100:649–662CrossRefPubMed

25.

Shanker A, Sayers T (2007) Sensitizing tumor cells to immune-mediated cytotoxicity. Adv Exp Med Biol 601:163–171PubMed

26.

Takeda K, Kojima Y, Ikejima K, Harada K, Yamashina S, Okumura K, Aoyama T, Frese S, Ikeda H, Haynes NM, Cretney E, Yagita H, Sueyoshi N, Sato N, Nakanuma Y, Smyth MJ (2008) Death receptor 5-mediated apoptosis contributes to cholestatic liver disease. Proc Natl Acad Sci USA 105:10895–10900CrossRefPubMed

27.

Takeda K, Yamaguchi N, Akiba H, Kojima Y, Hayakawa Y, Tanner JE, Sayers TJ, Seki N, Okumura K, Yagita H, Smyth MJ (2004) Induction of tumor-specific T cell immunity by anti-DR5 antibody therapy. J Exp Med 199:437–448CrossRefPubMed

28.

Uno T, Takeda K, Kojima Y, Yoshizawa H, Akiba H, Mittler RS, Gejyo F, Okumura K, Yagita H, Smyth MJ (2006) Eradication of established tumors in mice by a combination antibody-based therapy. Nat Med 12:693–698CrossRefPubMed

29.

VanOosten RL, Griffith TS (2007) Activation of tumor-specific CD8+ T Cells after intratumoral Ad5-TRAIL/CpG oligodeoxynucleotide combination therapy. Cancer Res 67:11980–11990CrossRefPubMed

30.

Wagner H (2002) Interactions between bacterial CpG-DNA and TLR9 bridge innate and adaptive immunity. Curr Opin Microbiol 5:62–69CrossRefPubMed

31.

Xiang H, Fox JA, Totpal K, Aikawa M, Dupree K, Sinicropi D, Lowe J, Escandon E (2002) Enhanced tumor killing by Apo2L/TRAIL and CPT-11 co-treatment is associated with p21 cleavage and differential regulation of Apo2L/TRAIL ligand and its receptors. Oncogene 21:3611–3619CrossRefPubMed

32.

Yamamoto S, Yamamoto T, Nojima Y, Umemori K, Phalen S, McMurray DN, Kuramoto E, Iho S, Takauji R, Sato Y, Yamada T, Ohara N, Matsumoto S, Goto Y, Matsuo K, Tokunaga T (2002) Discovery of immunostimulatory CpG-DNA and its application to tuberculosis vaccine development. Jpn J Infect Dis 55:37–44PubMed

33.

Zou W, Chen S, Liu X, Yue P, Sporn MB, Khuri FR, Sun SY (2007) c-FLIP downregulation contributes to apoptosis induction by the novel synthetic triterpenoid methyl-2-cyano-3, 12-dioxooleana-1, 9-dien-28-oate (CDDO-Me) in human lung cancer cells. Cancer Biol Ther 6:1614–1620PubMedCrossRef

Title: Optimized combination therapy using bortezomib, TRAIL and TLR agonists in established breast tumors
Authors: Sujin Lee
Hideo Yagita
Thomas J. Sayers
Esteban Celis
Publication date: 01-07-2010
Publisher: Springer-Verlag
Published in: Cancer Immunology, Immunotherapy / Issue 7/2010
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-010-0834-0

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 7/2010

Induction of tumor-specific acquired immunity against already established tumors by selective stimulation of innate DEC-205+ dendritic cells

Thrombin facilitates invasion of ovarian cancer along peritoneum by inducing monocyte differentiation toward tumor-associated macrophage-like cells

The anti-tumor effect of Newcastle disease virus HN protein is influenced by differential subcellular targeting

Expression of toll-like receptor 4 is down-regulated during progression of cervical neoplasia

(E)-4-Hydroxy-3-methyl-but-2 enyl pyrophosphate-stimulated Vγ9Vδ2 T cells possess T helper type 1-promoting adjuvant activity for human monocyte-derived dendritic cells

Th17 cells: positive or negative role in tumor?

Keynote webinar | Spotlight on antibody–drug conjugates in cancer